Human papillomavirus and cervical cancer

Crosbie, Emma J; Einstein, Mark H; Franceschi, Silvia; Kitchener, Henry C

doi:10.1016/s0140-6736(13)60022-7

Cited by 946 publications

(787 citation statements)

References 95 publications

Supporting

Mentioning

722

Contrasting

Unclassified

Order By: Relevance

“…HPV16 prevalence (%) in sexually active women aged 15–35 years (Data are from IARC Prevalence Surveys, 1990–2016) 5. The size of the dot is proportional to the number of women recruited in each survey.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Impacts of human papillomavirus vaccination for different populations: A modeling study

Baussano

Lazzarato

Ronco³

et al. 2018

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

International variations in the prevalence of HPV infection derive from differences in sexual behaviors, which are also a key factor of the basic reproductive number (R0) of HPV infection in different populations. R 0 affects the strength of herd protection and hence the impact of a vaccination program. Similar vaccination programs may therefore generate different levels of impact depending upon the population's pre‐vaccination HPV prevalence. We used IARC's transmission model to estimate (i) the overall effectiveness of vaccination versus no vaccination in women aged 15–34 years measured as percent prevalence reduction (%PR) of HPV16 and (ii) the corresponding herd protection in populations with gender‐equal or traditional sexual behavior and with different levels of sexual activity, corresponding to pre‐vaccination HPV16 prevalence from 1 to 8% as observed worldwide. Between populations with different levels of gender‐equal sexual activity, the highest difference in %PR under girls‐only vaccination is observed at 40% coverage (91%PR vs. 48%PR for 1% and 8% pre‐vaccination prevalence, respectively). HPV16 elimination is obtained with 55 and 97% coverage, respectively. To achieve desirable levels of HPV16 prevalence after vaccination, different levels of coverage are required in populations with different levels of pre‐vaccination HPV16 prevalence, for example, in populations with gender‐equal sexual behavior a decrease to 1/1000 HPV16 from pre‐vaccination prevalence of 1 and 8% would require coverages of 37 and 96%, respectively. In traditional populations, corresponding coverages would need to be 28 and 93%, respectively. In conclusion, pre‐vaccination HPV prevalence strongly influences herd immunity and helps predict the overall effectiveness of HPV vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Worldwide, more than 10‐fold differences are being reported in HPV prevalence5 mainly related to differences in sexual activity patterns and, in some regions, to the prevalence of human immunodeficiency virus (HIV), which is associated with increased acquisition6 and persistence7 of HPV infection.…”

Section: Introductionmentioning

confidence: 99%

Impacts of human papillomavirus vaccination for different populations: A modeling study

Baussano

Lazzarato

Ronco³

et al. 2018

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Interleukin-6 (IL-6), an important pro-inflammatory cytokine, is a multifunctional protein principally involved in the genesis and maintenance of the inflammatory response (Hamaguchi et al, 2011;Ma et al, 2011;Mosaad et al, 2012;Tao et al, 2012;Crosbie et al, 2013). The human IL-6 gene is organized into five exons and four introns and maps to the short arm of chromosome 7…”

Section: Introductionmentioning

confidence: 99%

Stratification Analysis and Case-control Study of Relationships between Interleukin-6 Gene Polymorphisms and Cervical Cancer Risk in a Chinese Population

Shi¹,

Líu²,

Wu³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The virus exclusively infects epithelium and produces new viral particles only in fully mature epithelial cells. Human papillomavirus disrupts normal cell-cycle control, promoting uncontrolled cell division, and the accumulation of genetic damage [32]. Hemaiswarya et al's [33] study of combination of phenylpropanoids 7 with 5-fluorouracil as anticancer agents against human cervical cancer (HeLa) cell line.…”

Section: Anticancer Activity Of Phenylpropanoids Eu Scaffold and Itsmentioning

confidence: 99%

Phenylpropanoids, Eugenol Scaffold, and Its Derivatives as Anticancer

Fadilah

Yanuar²,

Arsianti³

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Eugenol (EU) is a phenylpropene, an allyl chain-substituted guaiacol. EU is a member of the phenylpropanoids class of chemical compounds. It is a colorless to pale yellow oily liquid extracted from certain essential oils especially from clove oil. Further, chemopreventive agents might be used singly or in combination with chemotherapy or radiotherapy for the more effective treatment of cancer by enhancing the efficacy of these modalities with minimal side effects and toxicity. Considering that EU scaffold may be a prospective chemopreventive agent, its potent antitumor ability to interfere with solid cancer cell growth and its molecular mechanism were evaluated as an initiative toward the development of a novel strategy for cancer treatment. This review article will conduct that EU as the antiproliferative activity and molecular mechanism of the EU induced apoptosis against the cancer cells and animal models.

show abstract

Human papillomavirus and cervical cancer

Cited by 946 publications

References 95 publications

Impacts of human papillomavirus vaccination for different populations: A modeling study

Impacts of human papillomavirus vaccination for different populations: A modeling study

Stratification Analysis and Case-control Study of Relationships between Interleukin-6 Gene Polymorphisms and Cervical Cancer Risk in a Chinese Population

Phenylpropanoids, Eugenol Scaffold, and Its Derivatives as Anticancer

Contact Info

Product

Resources

About